Phase 3 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and agree to sign a consent form before any study procedures begin
• People aged 18 or older, of any sex
• People who weigh at least 40 kg or have a body mass index (BMI) of 18.5 or above
• People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scoring system called ECOG (scores 0 or 1, meaning fully active or able to carry out light activity)
• People with a life expectancy of at least 3 months
• People who have been confirmed through a tissue or cell sample to have a type of stomach or stomach-oesophagus junction cancer (called adenocarcinoma) that has spread or cannot be surgically removed
• People whose tumour has tested positive for a specific protein called CCR8, confirmed by the trial's central laboratory
• People whose cancer has tested negative or low for a protein called HER2
• People whose cancer has continued to grow during or after standard first-line treatment, or who had to stop that treatment due to side effects
• People who have at least one measurable area of cancer visible on scans
• People whose blood and organ function (such as liver, kidneys, and bone marrow) meets the laboratory thresholds required by the trial
• Women who could become pregnant must have a negative pregnancy test, must not be breastfeeding, and all people of reproductive potential must agree to use effective contraception throughout the study and for 6 months after the last dose

Who may not be able to join:

• People who have previously received a treatment targeting the CCR8 protein or other drugs that act on a type of immune cell called regulatory T cells (Tregs)
• People who have received cancer treatments such as chemotherapy, radiation, biological therapy, immunotherapy, or certain herbal medicines within 2 to 4 weeks before the first dose (the exact timeframe depends on the specific drug used)
• People whose cancer progressed within 2 months or less of starting a specific type of immunotherapy called anti-PD-(L)1 antibody treatment
• People who received a live vaccine within 4 weeks before the first dose
• People who had major surgery or an interventional procedure within 4 weeks before the first dose
• People who have been taking higher-dose steroid medicines (more than 10 mg of prednisone or equivalent per day) or other medicines that suppress the immune system within 2 weeks before the first dose
• People who still have significant side effects (above a mild level) from previous cancer treatment, or who experienced serious immune-related reactions during prior immunotherapy
• People whose cancer is a different type than the one specified for this trial
• People with uncontrolled fluid build-up in body cavities (such as the abdomen or chest)
• People with unstable or worsening cancer spread to the brain or the lining around the brain
• People with a known history of autoimmune disease
• People with known allergies or contraindications to the study drugs
• People whom the trial investigator considers unsuitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.